Xalkori (crizotinib): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1564492295

Back Back to the list of medications

Medication indications

Xalkori 200mg and 250mg hard capsule

XALKORI as monotherapy is indicated for:

• The first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

• The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

• The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)


Route of administration: Oral
Molecule: crizotinib

Patients' opinions on Xalkori

In brief

General satisfaction level: Be the first to evaluate

Treatment's effectiveness: Be the first to evaluate

Ease of use: Be the first to evaluate

Adherence to prescription: Be the first to evaluate

Detected side effects: Be the first to evaluate

Improvement in the quality of life: Be the first to evaluate

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.

Conditions related to this medication

Fact sheet

Lung cancer

See the fact sheet